Gbyli, Rana http://orcid.org/0000-0001-5524-0739
Song, Yuanbin http://orcid.org/0000-0001-5580-5998
Liu, Wei
Gao, Yimeng http://orcid.org/0000-0003-2954-2789
Biancon, Giulia
Chandhok, Namrata S.
Wang, Xiaman
Fu, Xiaoying
Patel, Amisha
Sundaram, Ranjini
Tebaldi, Toma http://orcid.org/0000-0002-0625-1631
Mamillapalli, Padmavathi
Zeidan, Amer M.
Flavell, Richard A. http://orcid.org/0000-0003-4461-0778
Prebet, Thomas http://orcid.org/0000-0002-6872-625X
Bindra, Ranjit S.
Halene, Stephanie http://orcid.org/0000-0002-2737-9810
Article History
Received: 9 August 2021
Revised: 11 February 2022
Accepted: 17 February 2022
First Online: 10 March 2022
Competing interests
: Zeidan: AMZ received research funding from <i>Celgene</i>/<i>BMS</i>, <i>Abbvie</i>, <i>Astex</i>, <i>Pfizer</i>, <i>Medimmune</i>/<i>AstraZeneca</i>, <i>Boehringer-Ingelheim</i>, <i>Trovagene/Cardiff Oncology</i>, <i>Incyte</i>, <i>Takeda</i>, <i>Novartis</i>, <i>Aprea</i>, <i>Amgen</i>, and <i>ADC Therapeutics</i>. AMZ participated in advisory boards, had a consultancy with, and/or received honoraria from <i>AbbVie</i>, <i>Otsuka</i>, <i>Pfizer</i>, <i>Celgene</i>/<i>BMS</i>, <i>Jazz</i>, <i>Incyte</i>, <i>Agios</i>, <i>Boehringer-Ingelheim</i>, <i>Novartis</i>, <i>Acceleron</i>, <i>Astellas</i>, <i>Daiichi Sankyo, Cardinal Health</i>, <i>Taiho</i>, <i>Seattle Genetics</i>, <i>BeyondSpring</i>, <i>Trovagene/Cardiff Oncology</i>, <i>Takeda</i>, <i>Ionis</i>, <i>Amgen</i>, <i>Tyme</i>, <i>Aprea</i>, <i>Kura</i>, <i>Janssen</i>, <i>Gilead</i>, and <i>Epizyme</i>. AMZ received travel support for meetings from <i>Pfizer</i>, <i>Novartis</i>, and <i>Trovagene</i>. Flavell: RAF is an advisor to Glaxo Smith Kline, Zai labs and Ventus Therapeutics. Prebet: <i>Boehringer Ingelheim:</i> Research Funding; <i>Novartis:</i> Honoraria; <i>Pfizer:</i> Honoraria; <i>Agios:</i> Consultancy, Research Funding; <i>Jazz Pharmaceuticals:</i> Consultancy, Honoraria, Research Funding; <i>Genentech</i>: Consultancy; <i>Tetraphase</i>: Consultancy; <i>Bristol-Myers Squibb</i>: Honoraria, Research Funding. Bindra: <i>Cybrexa Therapeutics</i>: Consultancy, Equity Ownership. <i>Athena Therapeutics:</i> Equity Ownership. Halene: <i>FORMA Therapeutics:</i> Consultancy.